Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Top Cited Papers
Open Access
- 1 January 2021
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (1), 28-35
- https://doi.org/10.1148/radiol.2020202903
Abstract
Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] 2; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.Keywords
Funding Information
- Bayer Fund
- GE Healthcare
This publication has 40 references indexed in Scilit:
- Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic diseaseClinical Kidney Journal, 2012
- Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendationsJournal of the American Academy of Dermatology, 2011
- Validation of the revised Schwartz estimating equation in a predominantly non-CKD populationPediatric Nephrology, 2010
- Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrolClinical Kidney Journal, 2010
- Risk factors for NSF: A literature reviewJournal of Magnetic Resonance Imaging, 2009
- Role of thermodynamic and kinetic parameters in gadolinium chelate stabilityJournal of Magnetic Resonance Imaging, 2009
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Does gadolinium-based angiography protect against contrast-induced nephropathy?: A systematic review of the literatureCatheterization and Cardiovascular Interventions, 2008
- New Insights into Nephrogenic Systemic FibrosisJournal of the American Society of Nephrology, 2007
- Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failureNephrology Dialysis Transplantation, 2007